The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer

References

• Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr. Treat. Options Oncol. 13(3), 377–389 (2012).
   PubMed Web of Science ®Google Scholar
• Yarom N, Jonker DJ. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov. Med. 11(57), 95–105 (2011).
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Price TJ, Chong G et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J. Clin. Oncol. 30(13), 1505–1512 (2012).
   PubMed Web of Science ®Google Scholar
• Welsh JW, Komaki R, Amini A et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J. Clin. Oncol. 31(7), 895–902 (2013).
   PubMed Web of Science ®Google Scholar
• Patel R, Leung HY. Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Curr. Pharm. Des. 18(19), 2672–2679 (2012).
   PubMed Web of Science ®Google Scholar
• Troiani T, Martinelli E, Capasso A et al. Targeting EGFR in pancreatic cancer treatment. Curr. Drug Targets. 13(6), 802–810 (2012).
   PubMed Web of Science ®Google Scholar
• Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets. 16(1), 15–31 (2012).
   PubMed Web of Science ®Google Scholar
• Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov. Med. 14(76), 207-–214 (2012).
   PubMed Web of Science ®Google Scholar
• Liakakos T, Fatourou E, Ziogas D, Lykoudis E, Roukos DH. Targeting VEGF, EGFR, and other interacting pathways for gastric cancer-promises and reality. Ann. Surg. Oncol. 15(10), 2981–2982 (2008).
   PubMed Web of Science ®Google Scholar
• Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr. Treat. Options Oncol. 13(3), 377–389 (2012).
   PubMed Web of Science ®Google Scholar
• Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat. Rev. Clin. Oncol. 8(8), 492–503 (2011).
   PubMed Web of Science ®Google Scholar
• García I, Vizoso F, Martín A et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann. Surg. Oncol. 10(3), 234–241 (2003).
   PubMed Web of Science ®Google Scholar
• Ettinger DS. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist 11(4), 358–373 (2006).
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim HP, Im SA et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 272(2), 296–306 (2008).
   PubMed Web of Science ®Google Scholar
• Inokuchi M, Murayama T, Hayashi M et al. Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer. Exp. Ther. Med. 2(2), 251–256 (2011).
   PubMed Web of Science ®Google Scholar
• Terashima M, Kitada K, Ochiai A et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin. Cancer Res. 18(21), 5992–6000 (2012).
   PubMed Web of Science ®Google Scholar
• Lieto E, Ferraraccio F, Orditura M et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann. Surg. Oncol. 15(1), 69–79 (2008).
   PubMed Web of Science ®Google Scholar
• Atmaca A, Werner D, Pauligk C et al. The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer 12, 524 (2012).
   PubMed Web of Science ®Google Scholar
• Matsubara J, Yamada Y, Hirashima Y et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin. Cancer Res. 14(10), 3022–3029 (2008).
   PubMed Web of Science ®Google Scholar
• Jácome AA, Wohnrath DR, Scapulatempo Neto C et al. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. Gastric Cancer. ( doi:10.1007/s10120-013-0236-z) (2013) ( Epub ahead of print).
   Google Scholar
• Zhang J, Zhan Z, Wu J et al. Association among polymorphisms in EGFR gene exons, lifestyle and risk of gastric cancer with gender differences in Chinese han subjects. PLoS One 8(3), e59254 (2013).
   Web of Science ®Google Scholar
• Han SW, Oh DY, Im SA et al. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Sci. 101(3), 793–799 (2010).
   PubMed Web of Science ®Google Scholar
• Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 8, 10 (2008).
   Google Scholar
• Liu Z, Liu L, Li M et al. Epidermal growth factor receptor mutation in gastric cancer. Pathology. 43(3), 234–238 (2011).
   PubMed Web of Science ®Google Scholar
• Becker JC, Müller-Tidow C, Stolte M et al. Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. Int. J. Oncol. 29(3), 615–623 (2006).
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Oue N, Sentani K et al. Liver-intestine cadherin induction by epidermal growth factor receptor is associated with intestinal differentiation of gastric cancer. Cancer Sci. 103(9), 1744–1750 (2012).
   PubMed Web of Science ®Google Scholar
• Hirao T, Sawada H, Koyama F et al. Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer. Cancer Gene Ther. 6(5), 423–427 (1999).
   PubMed Web of Science ®Google Scholar
• Jiang L, Lan T, Chen Y et al. PKG II Inhibits EGF/EGFR-Induced Migration of Gastric Cancer Cells. PLoS One 8(4), e61674 (2013).
   Web of Science ®Google Scholar
• Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr. Opin. Cell Biol. 21(2), 185–193 (2009).
   PubMed Web of Science ®Google Scholar
• Merlo V, Longo M, Novello S, Scagliotti GV. EGFR pathway in advanced non-small cell lung cancer. Front. Biosci. (Schol. Ed.). 3, 501–517 (2011).
   PubMedGoogle Scholar
• Han W, Lo HW. Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 318(2), 124–134 (2012).
   PubMed Web of Science ®Google Scholar
• Liao G, Wang Z, Zhang N, Dong P. Dominant negative epidermal growth factor receptor inhibits growth of human gastric cancer cells by inducing cell cycle arrest and apoptosis. Cancer Biother. Radiopharm. ( doi:10.1089/cbr.2012.1399) (2013) ( Epub ahead of print).
   Google Scholar
• Liao G, Wang Z, Zhao L, Zhang N, Dong P. Inhibitory effects of cytoplasmic-domain substituted epidermal growth factor receptor on growth, invasion and angiogenesis in human gastric cancer cells. Mol. Med. Rep. 3(2), 287–294 (2010).
   PubMed Web of Science ®Google Scholar
• Caruso R, Pallone F, Fina D et al. Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am. J. Pathol. 169(1), 268–278 (2006).
   PubMed Web of Science ®Google Scholar
• Dan L, Jian D, Na L, Xiaozhong W. Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901. Onco Targets Ther. 5, 271–277 (2012).
   PubMed Web of Science ®Google Scholar
• Norguet E, Dahan L, Seitz JF. Targetting esophageal and gastric cancers with monoclonal antibodies. Curr. Top. Med. Chem. 12(15), 1678–1682 (2012).
   PubMed Web of Science ®Google Scholar
• Heindl S, Eggenstein E, Keller S et al. Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. J. Cancer Res. Clin. Oncol. ( doi:10.1007/s00432-011-1128-4) (2012) ( Epub ahead of print).
   Google Scholar
• Kneissl J, Keller S, Lorber T et al. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines. Int. J. Oncol. 41(2), 733–744 (2012).
   PubMed Web of Science ®Google Scholar
• Hara M, Nakanishi H, Tsujimura K et al. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. Cancer Sci. 99(7), 1471–1478 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang J, Ji J, Yuan F et al. EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism. Zhonghua Zhong Liu Za Zhi. 31(2), 85–89 (2000).
   Google Scholar
• Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer. 15(3), 252–64 (2012).
   PubMed Web of Science ®Google Scholar
• Luo HY, Wei W, Shi YX et al. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol. Rep. 23(6), 1735–1745 (2010).
   PubMed Web of Science ®Google Scholar
• Fukuda K, Saikawa Y, Takahashi M et al. Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells. Int. J. Oncol. 40(4), 975–982 (2012).
   PubMed Web of Science ®Google Scholar
• Kobunai T, Watanabe T, Fukusato T. Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo. Anticancer Res. 31(11), 3691–3696 (2011).
   PubMed Web of Science ®Google Scholar
• Yamashita-Kashima Y, Iijima S, Yorozu K et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin. Cancer Res. 17(15), 5060–5070 (2011).
   PubMed Web of Science ®Google Scholar
• Shiraishi K, Mimura K, Izawa S et al. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer. (2012) ( Epub ahead of print).
   Google Scholar
• Wainberg ZA, Anghel A, Desai AJ et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 16(5), 1509–1519 (2010).
   PubMed Web of Science ®Google Scholar
• LaBonte MJ, Manegold PC, Wilson PM et al. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int. J. Cancer. 125(12), 2957–2969 (2009).
   PubMed Web of Science ®Google Scholar
• Shibata T, Kan H, Murakami Y et al. Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. Mol. Cancer Ther. 12(5), 737–746 (2013).
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Ikehara Y, Kodera Y et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br. J. Cancer 95(11), 1504–1513 (2006).
   PubMed Web of Science ®Google Scholar
• Kishida O, Miyazaki Y, Murayama Y et al. Gefitinib (“Iressa”, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother. Pharmacol. 55(4), 393–403 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu S, Belkhiri A, El-Rifai W. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. Gastroenterology 141(5), 1738–1748 (2011).
   PubMed Web of Science ®Google Scholar
• Piontek M, Hengels KJ, Porschen R, Strohmeyer G. Antiproliferative effect of tyrosine kinase inhibitors in epidermal growth factor-stimulated growth of human gastric cancer cells. Anticancer Res. 13(6A), 2119–2123 (1993).
   PubMed Web of Science ®Google Scholar
• Nam HJ, Ching KA, Kan J et al. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol. Cancer Ther. 11(2), 439–451 (2012).
   PubMed Web of Science ®Google Scholar
• Chan JA, Blaszkowsky LS, Enzinger PC et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann. Oncol. 22(6), 1367–1373 (2011).
   PubMed Web of Science ®Google Scholar
• Lordick F, Luber B, Lorenzen S et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the arbeitsgemeinschaft internistische onkologie (AIO). Br. J. Cancer. 102(3), 500–505 (2010).
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Lin LS, DiCarlo B et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br. J. Cancer. 105(6), 760–765 (2011).
   PubMed Web of Science ®Google Scholar
• Iqbal S, Goldman B, Fenoglio-Preiser CM et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann. Oncol. 22(12), 2610–2615 (2011).
   PubMed Web of Science ®Google Scholar
• Bamias A, Karina M, Papakostas P et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother. Pharmacol. 65(6), 1009–1021 (2010).
   PubMed Web of Science ®Google Scholar
• Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 14(6), 481–489 (2013).
   PubMed Web of Science ®Google Scholar
• Wei X. Mechanism of EGFR-related cancer drug resistance. Anticancer Drugs 22(10), 963–970 (2011).
   PubMed Web of Science ®Google Scholar